Free Letter - District Court of Delaware - Delaware

Case 1:04-cv—00171-G|\/IS Document 143-2 Filed 08/15/2006 Page 1 0f 3
EXHIBIT A

Case 1 :04-cv-00171-GIVIS Document 143-2 Filed 08/15/2006 Page 2 of 3
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
éijI$iE>"E§5L%i`iZiiIfi`iE ``'``I````_```““**`M”""*`”`` I
Plaintiff, Civil Action No. €)4~17l·ICAJ
TEVA PHARMACEUTICALS USA, INC. and STIPULATION AND ORDER
TEVA PHARMACEUTICAL INDUSTRIES :
LIMITED :
Defendants. :
t...........i.t.t............ii..,,t..............i» - .....Mt... Qi
IT IS HEREBY STIPULATED AND AGREED by and between Plaintiff Glaxo Group
Limited ("Glaxo”) and Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical
Industries Ltd. (together, "Teva") as follows:
I. Teva shall not offer for sale, sell and/or distribute in the United States, Ranitidine
Oral Solution USP, 15 mg/mL, as described in Abbreviated New Drug
Application ("ANDA”) No. 76-93 7, from the date of this Stipulation and Order
until at least ten (I0) days after Teva provides notice via facsimile to Glaxo’s
counsel, Brian P. Murphy and Thomas J. Puppa, that Teva has received Eood and
Drug Administration (“FDA") approval of ANDA No. 76-937; except that the
foregoing provision will not apply in the event that the aforementioned FDA
approval of ANDA No. 76-937 is obtained after a final judgment disposing of all
issues is entered in this action by this Court;
2. Glaxo reserves the right to file a motion pursuant to Fed. R. Civ. P. 65 for a inter
parties Temporary Restraining Order and/or Preliminary Inj unction en} oining
Teva from offering for sale, selling andfor distributing in the United States,
Ranitidine Oral Solution USP, I5 nig/mL, as described in ANDA No. 76-937,
i-Nv:20s932s.s

Case 1 :04-cv-00171-GIVIS Document 143-2 Filed 08/15/2006 Page 3 of 3
during the ten (10) days after G1axo’s counsel receives the notice described in
paragraph 1. The parties agree to seek an expedited hearing on any such motion
by Glaxo as contemplated by Fed. R. Civ. P. 65.
Dated: August 15, 2006 Dated: August 15, 2006
For Plaintiff GLAXO GROUP LIMITED For Defendants TEVA
PHARMACEUTICALS USA, INC. and
TEVA PHARMACEUTICAL
INDUSTRIES LIM1TED
By: /s/ Francis DiGiovanni By: /s/ Jesy W. Irtersoii
Francis DiGiovanni (#3189) Josy W. Ingersoll (#1088)
CONNOLLY BOVE LODGE YOUNG CONAWAY STARGATT
& I-IUTZ LLP & TAYLOR, LLP
The Nemours Building The Brandywine Building
1007 North Orange Street 1000 West Street, 17th Floor
P.O. Box 2207 P.O. Box 391
Wilmington, DE 19899-2207 Wilmington, DE 19899-0391
(302) 888-6316 (302) 571-6600
OF COUNSEL: OF COUNSEL:
Brian P. Murphy Mark D. Schuman
Thomas J. Puppa Jeffrey C. Brown
Bryan J. Vogel MERCHANT & GOULD
Oren D. Langer 3200 IDS Center
MORGAN, LEWIS & BOCKIUS LLP 80 Seuth 8th Street
101 Park Avenue Minneapolis, 1\/IN 55402
New York, NY 10178-0060 (612) 332-5300
(212) 309-6000
Atterizeysfer Defendants Teva
Attorneys for Plairzrf Glaxo Group Pharmaceuticals USA, Inc. and Teva
Limited Pharmaceutical Industries Limited
SO ORDERED this day of 2006.
I-ION. KENT A. JORDAN
UN1TED STATES DISTRICT JUDGE
2

Case 1:04-cv-00171-GMS

Document 143-2

Filed 08/15/2006

Page 1 of 3

Case 1:04-cv-00171-GMS

Document 143-2

Filed 08/15/2006

Page 2 of 3

Case 1:04-cv-00171-GMS

Document 143-2

Filed 08/15/2006

Page 3 of 3